← Back to guidelines
Infectious Disease3 papers

Chronic fibrosing pulmonary aspergillosis

Last edited: 4/10/2026

Overview

Chronic pulmonary aspergillosis (CPA) is a progressive fungal disease that can develop in patients with underlying lung conditions 1. It frequently occurs in survivors of pulmonary tuberculosis (TB), contributing to post-TB lung disease 1.

Diagnosis

  • Diagnosis of CPA in TB survivors is based on clinical symptoms, radiographic abnormalities, and microbiological evidence 1.
  • Prevalence of CPA among patients with TB varies: 9% during treatment and 13% posttreatment 1.
  • Among patients with persistent respiratory symptoms after TB treatment, CPA prevalence is significantly higher, reaching 48% 1.
  • Management

  • No specific management strategies are detailed in the provided abstracts.
  • Special Populations

  • No specific information on special populations is covered in the provided abstracts.
  • Key Recommendations

  • Consider CPA in patients with persistent respiratory symptoms following pulmonary tuberculosis treatment 1. (Evidence: Moderate)
  • Recognize that CPA prevalence is higher in patients with persistent respiratory symptoms after TB treatment (up to 48%) compared to the general TB population (9-13%) 1. (Evidence: Moderate)
  • References

    1 Madden AE, Ofori SK, Budu M, Sisay E, Dooley B, Murray MB. A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025. link

    Original source

    1. [1]
      A Systematic Review of Chronic Pulmonary Aspergillosis Among Patients Treated for Pulmonary Tuberculosis.Madden AE, Ofori SK, Budu M, Sisay E, Dooley B, Murray MB Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG